Who is sponsoring NCT04568057?

NCT04568057 is sponsored by Maculume Ltd..

What drugs are being tested in NCT04568057?

Interventions in NCT04568057: NIR Transcranial phototherapy device, Placebo Transcranial Device.

What condition does NCT04568057 study?

NCT04568057 studies Age-related Cognitive Decline.

Is NCT04568057 still recruiting?

NCT04568057 is currently completed. Last updated 23 February 2021.

Last reviewed 2021-02-23 · How we verify

NCT04568057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Transcranial NIR Light Upon Memory

Completed NA Last updated 23 February 2021

What this trial tests

NA trial testing NIR Transcranial phototherapy device in Age-related Cognitive Decline in 35 participants. Completed in 31 December 2020.

Timeline

1 June 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Maculume Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	35
Start date	1 June 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

NIR Transcranial phototherapy device
Placebo Transcranial Device

Conditions studied

Age-related Cognitive Decline — all drugs for Age-related Cognitive Decline →

Sponsor

Maculume Ltd.

Who can join

Adults 45 to 80, any sex, with Age-related Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A double-blind placebo-controlled study evaluating the effect of 1068nm NIR trans-cranial phototherapy upon the cognitive function of healthy individuals between the age of 45 years and 80 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Transcranial Near-Infrared Light 1068 nm Upon Memory Performance in Aging Healthy Individuals: A Pilot Study.
Dougal G, Ennaceur A, Chazot PL. · · 2021 · cited 12× · PMID 34662523 · DOI 10.1089/photob.2020.4956

Verify or expand the search:

Other recruiting trials for Age-related Cognitive Decline

Currently open trials in the same condition.

NCT06948136 — Acute Effects of THC in Older Adult · Phase 1 · recruiting
NCT06964399 — The Effect of Reminiscence Therapy in Elderly · NA · recruiting
NCT06893432 — Cognitive Function and EEG Brain Network Remodeling Among Users of Hearing Aids With ARHL · active not recruiting
NCT06377254 — Multi-organ Responses to CHronic Physical Activity and INactivity · NA · recruiting
NCT04184375 — Cognitive Stimulation for Elderly Bipolar Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04568057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maculume Ltd.
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04568057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing